OHRP and FDA Issue Joint Guidance on Minutes of IRB Meetings
September 26, 2017
The Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA) have issued guidance titled, “Minutes of Institutional Review Board (IRB) Meetings: Guidance for Institutions and IRBs.” This guidance was prepared jointly by OHRP and FDA and is intended for institutions and IRBs responsible for oversight of human subject research under HHS and FDA regulations.
To enhance human subject protection and reduce regulatory burden, OHRP and FDA have been actively working to harmonize the Agencies’ regulatory requirements and guidance for human subject research. This guidance document was developed as a part of these efforts. In addition, on December 13, 2016, the 21st Century Cures Act (Cures Act) (Pub. L. 114-255) was signed into law. Title III, section 3023 of the Cures Act requires the Secretary of HHS to harmonize differences between the HHS human subject regulations and FDA’s human subject regulations. This guidance document is consistent with the goals of section 3023 of the Cures Act.
The purpose of the guidance is to assist institutions and IRBs in preparing and maintaining minutes of IRB meetings that meet the regulatory requirements for minutes set forth in HHS and FDA regulations. The guidance also provides general recommendations on the type and amount of information to be included in the minutes.
This joint guidance is now available on OHRP's website at https://www.hhs.gov/ohrp/regulations-and-policy/guidance/alphabetical-list/index.html and on FDA's website at https://www.fda.gov/RegulatoryInformation/Guidances/ucm470046.htm.
Content last reviewed on September 26, 2017